Medicare Claims Study Tracks Endocrinologist Uptake of 2019 ADA SGLT2i and GLP-1 RA Guidance

This observational analysis is not a new guideline but measures how the 2019 ADA Standards of Care shifted SGLT2i and GLP-1 RA fills among Medicare patients with T2D treated by endocrinologists, which tells pharmacists where implementation gaps persist.

📅 Journal publication: Oct 1, 2026 · Last updated: Oct 29, 2026

ADA Standards of Care 2019American Diabetes Associationtype 2 diabetesSGLT2 inhibitorsGLP-1 receptor agonistsprescribing patternsMedicare Endocrinology / Obesity

Background Information

Guideline updates boost SGLT2 inhibitor prescribing for diabetes care.

The study examines the impact of guidelines on prescribing patterns for key diabetes medications, relevant for optimizing patient outcomes. SGLT2 inhibitor prescribing increased by 11.4 percentage points and GLP-1 receptor agonist prescribing by 2.4 percentage points post-2019 ADA guideline update. Findings highlight the influence of guideline updates on prescribing behaviors, with variability linked to physician knowledge levels. SGLT2 inhibitor use increased significantly post-guideline, especially among knowledgeable endocrinologists.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Gray BM, Vandergrift J, Landon BE, McCoy R

Citation: Gray BM, Vandergrift J, Landon BE, et al. Prescribing SGLTis and GLP-1 RAs for Patients With Type 2 Diabetes, Guideline Updates, and Longitudinal Knowledge Assessment Scores. JAMA network open. 2026;9(10):e2640858. doi:10.1001/jamanetworkopen.2026.40858

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Founding member rate

$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.